Meridian Venture Partners II GP, L.P. - 21 Aug 2025 SCHEDULE 13D/A Report for ANI Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (ANIP)

Filing Manager
Meridian Venture Partners II GP, L.P.
Reporting Manager
Robert E. Brown, Jr.
Security
ANI Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share
Symbol
ANIP
Shares outstanding
21,553,542 shares
Disclosed Ownership
1,034,570 shares
Ownership
4.8%
Form type
SCHEDULE 13D/A
Filing time
22 Aug 2025, 08:00:22 UTC
Date of event
21 Aug 2025
Previous filing
13 Mar 2025
SEC
View on sec.gov

Quoteable Key Fact

"Meridian Venture Partners II GP, L.P. disclosed 4.8% ownership in ANI Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (ANIP) on 21 Aug 2025."

Quick Takeaways

  • Meridian Venture Partners II GP, L.P. filed SCHEDULE 13D/A for ANI Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (ANIP).
  • Disclosed ownership: 4.8%.
  • Date of event: 21 Aug 2025.

What Changed

  • Previous schedule filing date: 13 Mar 2025.
  • Current filing was accepted on 22 Aug 2025, 08:00.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Meridian Venture Partners II GP, L.P. ("GP") 4.7% 1,014,381 0 1,014,381 /s/ Robert E. Brown, Jr. Robert E. Brown, Jr. 0001580170
Meridian Venture Partners II, L.P. 4.7% 1,014,381 0 1,014,381 /s/ Robert E. Brown, Jr. Robert E. Brown, Jr. 0001109507
Meridian Venture Partners II, Co. 4.7% 1,014,381 0 1,014,381 /s/ Robert E. Brown, Jr. Robert E. Brown, Jr. 0001580169
Robert E. Brown, Jr. 4.8% 1,034,570 20,189 1,014,381 /s/ Robert E. Brown, Jr. Robert E. Brown, Jr. 0001579672
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .